MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-02-2026
Twist Bioscience Corporation Retained Earnings 2011-2026 | TWST
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Twist Bioscience Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.32 B | -1.24 B | -1.03 B | -828 M | -611 M | -458 M | -319 M | -211 M | -140 M | -80.3 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -80.3 M | -1.32 B | -624 M |
Quarterly Retained Earnings Twist Bioscience Corporation
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.35 B | -1.32 B | -1.29 B | -1.31 B | -1.27 B | -1.24 B | -1.21 B | -1.12 B | -1.08 B | -1.03 B | -987 M | -929 M | -870 M | -828 M | -777 M | -717 M | -656 M | -611 M | -569 M | -611 M | -491 M | -458 M | -458 M | -458 M | -374 M | -319 M | -319 M | -319 M | -233 M | -211 M | -211 M | -211 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -211 M | -1.35 B | -745 M |
Retained Earnings of other stocks in the Diagnostics research industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Agilent Technologies
A
|
348 M | $ 115.48 | 0.82 % | $ 35.1 B |  USA |
 |
Centogene N.V.
CNTG
|
-62.9 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Burning Rock Biotech Limited
BNR
|
-2.23 B | $ 16.2 | -0.61 % | $ 175 M |  China |
|
Biodesix
BDSX
|
-462 M | $ 15.07 | 2.1 % | $ 1.95 B | USA |
 |
Aspira Women's Health
AWH
|
-544 M | - | -6.19 % | $ 10.5 M | USA |
 |
Co-Diagnostics
CODX
|
-80.4 M | $ 4.4 | 101.83 % | $ 5.85 M | USA |
 |
Check-Cap Ltd.
CHEK
|
-170 M | - | - | $ 9.42 M |  Israel |
 |
Castle Biosciences
CSTL
|
-200 M | $ 24.84 | -0.84 % | $ 690 M | USA |
 |
DarioHealth Corp.
DRIO
|
-452 M | $ 8.4 | 3.7 % | $ 33.5 M | Israel |
 |
Oxford Immunotec Global PLC
OXFD
|
-84 M | - | - | $ 562 M |  Britain |
 |
BioNano Genomics
BNGO
|
-720 M | $ 1.2 | 0.84 % | $ 6.53 M | USA |
|
Akumin
AKU
|
-280 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Charles River Laboratories International
CRL
|
1.39 B | $ 173.89 | -0.58 % | $ 8.62 B | USA |
 |
Accelerate Diagnostics
AXDX
|
-607 M | - | -61.36 % | $ 2.46 M | USA |
 |
DexCom
DXCM
|
2.43 B | $ 62.22 | -0.24 % | $ 24.3 B | USA |
 |
Fulgent Genetics
FLGT
|
590 M | $ 16.82 | 2.31 % | $ 509 M | USA |
 |
Biomerica
BMRA
|
-53.2 M | $ 2.17 | -0.91 % | $ 4.98 M | USA |
 |
Global Cord Blood Corporation
CO
|
2.89 B | - | - | $ 399 M | China |
 |
Celcuity
CELC
|
-449 M | $ 112.63 | -0.27 % | $ 5.27 B | USA |
 |
Fluidigm Corporation
FLDM
|
-624 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-150 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-4.94 B | - | 0.12 % | $ 80.1 M | China |
 |
Exact Sciences Corporation
EXAS
|
-4.71 B | - | - | $ 19.8 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
440 M | - | - | $ 10.7 B | USA |
 |
DermTech
DMTK
|
-424 M | - | -11.32 % | $ 2.94 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
9.99 B | $ 198.02 | 0.17 % | $ 22 B | USA |
 |
Guardant Health
GH
|
-2.99 B | $ 93.83 | 2.94 % | $ 11.8 B | USA |
 |
Enzo Biochem
ENZ
|
-294 M | - | -8.98 % | $ 14.8 K | USA |
 |
Lantheus Holdings
LNTH
|
680 M | $ 76.1 | 0.53 % | $ 5.14 B | USA |
 |
Biocept
BIOC
|
-298 M | - | -13.05 % | $ 7.29 M | USA |
 |
Medpace Holdings
MEDP
|
-460 M | $ 498.34 | 1.81 % | $ 14.4 B | USA |
 |
Heska Corporation
HSKA
|
-169 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-230 M | - | -20.0 % | $ 1.06 M | USA |
 |
Interpace Biosciences
IDXG
|
-211 M | $ 1.96 | 5.82 % | $ 8.67 M | USA |
 |
Mettler-Toledo International
MTD
|
9.24 B | $ 1 259.94 | -1.11 % | $ 26 B |  Schweiz |
 |
ICON Public Limited Company
ICLR
|
2.72 B | $ 114.19 | 2.49 % | $ 9.42 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
6.39 B | $ 569.55 | 0.87 % | $ 45.8 B | USA |
 |
Neogen Corporation
NEOG
|
-536 M | $ 9.41 | 0.21 % | $ 2.04 B | USA |
 |
Illumina
ILMN
|
-1.24 B | $ 127.38 | 0.59 % | $ 20.3 B | USA |
 |
IQVIA Holdings
IQV
|
7.42 B | $ 173.26 | 0.5 % | $ 29.8 B | USA |
 |
Pacific Biosciences of California
PACB
|
-2.7 B | $ 1.34 | -0.74 % | $ 402 M | USA |
 |
QIAGEN N.V.
QGEN
|
2.75 B | - | - | $ 10.6 B |  Niderland |
 |
Motus GI Holdings
MOTS
|
-154 M | - | -34.28 % | $ 263 K | Israel |
 |
Chembio Diagnostics
CEMI
|
-154 M | - | 0.22 % | $ 16.8 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
8.64 B | $ 273.72 | 0.36 % | $ 22.8 B | USA |
 |
Myriad Genetics
MYGN
|
-1.12 B | $ 4.75 | 3.49 % | $ 440 M | USA |
 |
Sotera Health Company
SHC
|
-532 M | $ 14.96 | 0.61 % | $ 4.25 B | USA |
 |
NeoGenomics
NEO
|
-434 M | $ 8.0 | 3.23 % | $ 1.02 B | USA |
 |
National Research Corporation
NRC
|
-17.3 M | $ 17.16 | -1.04 % | $ 384 M | USA |